Top Qs
Timeline
Chat
Perspective

Glovadalen

D1 receptor positive allosteric modulator under development for Parkinson's disease From Wikipedia, the free encyclopedia

Glovadalen
Remove ads

Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors.[5][6] As of May 2024, glovadalen is in phase 2 clinical trials for this indication.[1][2][5] The drug is under development by UCB Biopharma.[1][4][5] It is described as an orally active, centrally penetrant small molecule.[1][5][6]

Quick facts Clinical data, Other names ...
Remove ads

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads